Corticosteroids for the treatment of joint pain
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
1. An injectable formulation comprising controlled- or sustained-release microparticles comprising a Class B corticosteroid and a poly(lactic-co-glycolic) acid copolymer (PLGA) matrix, wherein the Class B corticosteroid is budesonide or a pharmaceutically-acceptable salt thereof, wherein the budesonide comprises between 22% to 28% of the microparticles and wherein the PLGA has the following characteristics: (i) a molecular weight in the range of about 40 to 70 kDa; and (ii) a lactide:glycolide molar ratio of 80:20 to 60:40, wherein the budesonide or pharmaceutically acceptable salt thereof is released for between 14 days and 90 days at a rate that does not adversely suppress the hypothalamic-pituitary-adrenal axis (HPA axis).
2. The formulation of claim 1 , wherein the PLGA comprises an acid endcap.
3. The formulation of claim 1 , wherein the microparticles have a mean diameter of between 10 μm to 100 μm.
4. The formulation of claim 1 , wherein the PLGA has a molar ratio of lactic acid: glycolic acid of 75:25.
5. The formulation of claim 1 , wherein the microparticles further comprise a polyethylene glycol (PEG) moiety, wherein the PEG moiety comprises between 25% to 0% weight percent of the microparticle.
6. A method of treating pain or inflammation in a patient comprising administering to said patient a therapeutically effective amount of the controlled or sustained formulation of claim 1 .
7. The method of claim 6 , wherein the controlled or sustained release formulation is administered as one or more injections.
8. The method of claim 6 , wherein the patient has osteoarthritis, rheumatoid arthritis, acute gouty arthritis, or synovitis.
9. A method of treating pain or inflammation in a patient comprising administering to said patient a therapeutically effective amount of the controlled or sustained release formulation of claim 1 .
10. The method of claim 9 , wherein the controlled or sustained release formulation is administered as one or more injections.
11. The method of claim 9 , wherein the patient has osteoarthritis, rheumatoid arthritis, acute gouty arthritis, or synovitis.
12. A method of slowing, arresting or reversing progressive structural tissue damage associated with chronic inflammatory disease in a patient comprising administering to said patient a therapeutically effective amount of the controlled or sustained release formulation of claim 9 .
13. The method of claim 12 , wherein the controlled or sustained release preparation is administered as one or more injections.
14. The method of claim 12 , wherein the patient has osteoarthritis, rheumatoid arthritis, acute gouty arthritis, or synovitis.
15. A method of slowing, arresting or reversing progressive structural tissue damage associated with chronic inflammatory disease in a patient comprising administering to said patient a therapeutically effective amount of the controlled or sustained release formulation of claim 1 .
16. The method of claim 15 , wherein the controlled or sustained release formulation is administered as one or more injections.
17. The method of claim 15 , wherein the patient has osteoarthritis, rheumatoid arthritis, acute gouty arthritis, or synovitis.
18. A method of manufacturing the controlled or sustained release formulation of claim 1 , wherein the microparticles are manufactured using a solvent evaporation process wherein the budesonide is dispersed in a lactic acid-glycolic acid copolymer organic solution and the mixture is treated to remove the solvent from the mixture, thereby producing microparticles.
19. The method of claim 18 , wherein the solvent evaporation process utilizes a spray drying or fluid bed apparatus to remove the solvent and produce microparticles.
20. The method of claim 18 , wherein the solvent evaporation process utilizes a spinning disk.